Trintellix (vortioxetine) / Lundbeck, Takeda - LARVOL DELTA

QTc changes and early major adverse cardiovascular events associated with antidepressant treatment for major depressive disorder in adults: individual participant data network meta-regression of double blind randomised trials. (PubMed, BMJ) - "The effect of specific antidepressants on QTc interval differed between adults with depression. No evidence associated antidepressant use with early MACE and non-suicidal sudden death. To support shared decision making and taking into account the trade-off between benefits and harms, individual modifiable and non-modifiable risk factors should be considered when choosing antidepressants."

Adverse events • Clinical • Journal • Cardiovascular • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Vortioxetine enhances the anti-pancreatic cancer efficacy of gemcitabine through reducing MAOB expression. (PubMed, Front Pharmacol) - "Vortioxetine potentiates the antitumor efficacy of gemcitabine against pancreatic cancer, with its effects associated with reduced MAOB expression, enhanced apoptosis, and suppression of EMT. These findings support further investigation of vortioxetine combined with gemcitabine as a potential therapeutic strategy for overcoming chemoresistance in pancreatic cancer."

Journal • Oncology • Pancreatic Cancer • Solid Tumor • CASP3 • CDH1 • CDH2

Reversible Cerebral Vasoconstriction Syndrome Associated With Vortioxetine: A Case Report. (PubMed, Cureus) - "Vortioxetine was discontinued and replaced with trazodone following Liaison Psychiatry consultation. Prompt recognition, vascular imaging, and withdrawal of the suspected precipitating agent are essential to minimize the risk of neurological complications. Further case reports and pharmacovigilance studies are needed to better define the relationship between vortioxetine and RCVS."

Journal • CNS Disorders • Depression • Mood Disorders • Pain • Psychiatry

Comparative efficacy of interventions for transdiagnostic anhedonia: a network meta-analysis. (PubMed, Psychiatry Res) - "In the overall transdiagnostic network, estimates versus the pooled control node favoured vortioxetine 10 mg/day, left dorsolateral prefrontal cortex-targeted transcranial magnetic stimulation (left DLPFC-targeted TMS), behavioural activation, and meditation...Left DLPFC-targeted TMS showed the most consistent evidence pattern across the overall and major depressive disorder networks, supported by five direct trials in the overall network and stable leave-one-trial-out estimates. These findings clarify the comparative evidence across pharmacological, neuromodulatory, and psychological approaches and provide a structured basis for future diagnosis-specific trials and treatment development."

Journal • Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Schizophrenia

The multimodal antidepressant vortioxetine exerts therapeutic effects in male mice which is associated with normalization of hippocampal SIK2/CRTC1-related signaling and require hippocampal CRTC1. (PubMed, Front Pharmacol) - "Critically, hippocampal CRTC1 knockdown completely abolished the behavioral benefits of vortioxetine. These findings demonstrate that vortioxetine's antidepressant actions in male mice are associated with normalization of hippocampal SIK2/CRTC1-related signaling and require hippocampal CRTC1, providing a novel molecular mechanism underlying its multimodal efficacy."

Journal • Preclinical • CNS Disorders • Depression • Psychiatry • CRTC1

The effect of vortioxetine on cognitive function in older adults with major depressive disorder: A systematic review. (PubMed, J Affect Disord) - "Vortioxetine was associated with consistent reductions in depressive symptoms and with neutral-to-positive, predominantly domain-specific cognitive effects in late-life depression. Its effect on global cognition, and whether any cognitive benefit is independent of mood improvement, remain uncertain. Further longitudinal randomized studies are needed to clarify its clinical role."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Developmental Disorders • Major Depressive Disorder • Mood Disorders • Psychiatry

Adolescent obsessive-compulsive disorder presenting with internal dialogue: a case report. (PubMed, Front Psychiatry) - "Sertraline combined with psychotherapy produced minimal improvement...Treatment with vortioxetine and low-dose aripiprazole was followed by symptom reduction and a gradual return to school...Careful phenomenological assessment is important to avoid misdiagnosis and delayed treatment in similar cases. Symptom improvement was observed after treatment modification, although the relative contribution of medication changes, psychotherapy, family support, symptom fluctuation, and school re-engagement cannot be determined in a single case."

Journal • CNS Disorders • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry

CYP2D6 Allele and Metabolizer Phenotype Distribution in a Central Indian Depression Cohort: Interim Pharmacogenetic Findings (WFSBP 2026) - "These findings have direct implications for antidepressant prescribing. CYP2D6 PMs may experience higher exposure and adverse effects with paroxetine, fluvoxamine, venlafaxine, TCAs, and vortioxetine, while UMs risk subtherapeutic response. The substantial IM proportion may have altered dose requirements."

Biomarker • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • CYP2D6

Strong growth from Vyepti nd focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026 (TradingView) - "Revenue from Lundbeck's strategic brands increased by +17% CER (+11% DKK), reaching DKK 10,463 million, representing 77% of total revenue: Rexulti: DKK 3,297 million (+17% CER; +8% DKK; underlying +16% CER); Vyepti: DKK 2,865 million (+46% CER; +36% DKK; underlying +46% CER); Brintellix/Trintellix: DKK 2,331 million (+0% CER; -2% DKK; underlying -5% CER); Abilify LAI franchise: DKK 1,970 million (+7% CER; +4% DKK; underlying +4% CER)."

Sales • Autism Spectrum Disorder • Bipolar Disorder • Major Depressive Disorder • Migraine • Schizophrenia • Tourette Syndrome

The Antidepressant Vortioxetine Potently Inhibits Cell Growth in Cultured Human Glioblastoma Cells Expressing 5-HT1B Serotonin Receptors. (PubMed, Cells) - "Other antidepressants, i.e., fluoxetine and duloxetine, inhibited GBM cell growth only at high concentrations. Blocking 5-HT1B with SB224289 abolished the anti-GBM effect of Vx, even in cells expressing other Vx. These findings demonstrate that therapeutic concentrations of Vx inhibit GBM cell proliferation and suggest that this action may be mediated, at least in part, by 5-HT1B receptor activation."

Journal • Brain Cancer • CNS Disorders • CNS Tumor • Depression • Glioblastoma • Major Depressive Disorder • Oncology • Psychiatry • Solid Tumor

Comparative Clinical and Cognitive Outcomes of rTMS and Vortioxetine in Major Depressive Disorder. (PubMed, Acta Neuropsychiatr) - "rTMS and vortioxetine were associated with comparable improvements in depressive symptoms and cognitive functioning in patients with MDD. Baseline cognitive status appeared to be a stronger predictor of outcome than treatment modality."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Case Report: Oral semaglutide-associated depression in a patient with type 2 diabetes mellitus: a dose-dependent recurrence confirmed on rechallenge and managed with vortioxetine-bupropion combination therapy. (PubMed, Front Psychiatry) - "Vortioxetine 10 mg combined with bupropion XL 150 mg produced remission within 4 weeks (PHQ-9: 6). A Naranjo score of 7 puts the relationship in the probable range, though that reading is held back by the usual limits of a single case and by an incomplete washout before rechallenge. The step from 3 to 7 mg may be a point of raised psychiatric risk in vulnerable patients, and watching mood during titration looks like a sensible precaution."

Journal • CNS Disorders • Depression • Diabetes • Major Depressive Disorder • Metabolic Disorders • Mood Disorders • Psychiatry • Suicidal Ideation • Type 2 Diabetes Mellitus

Next-generation precision medicine for mood disorders: reproducible blood biomarkers enable objective diagnostics, subtyping, and targeted therapeutics. (PubMed, Mol Psychiatry) - "Top therapeutic matches for depression were omega-3 fatty acids, lithium, and vortioxetine; for bipolar depression lithium, valproate, and clozapine; and for mania lithium, valproate, and omega-3 fatty acids...Taken together, our results suggest that mood stabilizers, such as low-dose lithium, could be considered more often empirically first line in mood disorders patients, without or with the use of antidepressants, especially given the anti-suicidal properties. As mood disorders are highly prevalent, can severely affect quality of life, and lead to shortened lifespans, there is an urgent need for such insights, and for the added precision and personalization that biomarker tests can offer, to be applied to and improve clinical diagnosis, treatment, and prevention."

Biomarker • Journal • Addiction (Opioid and Alcohol) • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry • FOSL2

Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder (clinicaltrials.gov) - P3 | N=326 | Not yet recruiting | Sponsor: Chengdu Kanghong Pharmaceutical Group Co., Ltd.

New P3 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. (PubMed, Focus (Am Psychiatr Publ)) - "In head-to-head studies, agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine, and vortioxetine were more effective than other antidepressants (range of ORs 1·19-1·96), whereas fluoxetine, fluvoxamine, reboxetine, and trazodone were the least efficacious drugs (0·51-0·84). For acceptability, agomelatine, citalopram, escitalopram, fluoxetine, sertraline, and vortioxetine were more tolerable than other antidepressants (range of ORs 0·43-0·77), whereas amitriptyline, clomipramine, duloxetine, fluvoxamine, reboxetine, trazodone, and venlafaxine had the highest dropout rates (1·30-2·32)...These results should serve evidence-based practice and inform patients, physicians, guideline developers, and policy makers on the relative merits of the different antidepressants. National Institute for Health Research Oxford Health Biomedical Research Centre and the Japan Society for the Promotion of Science.Appeared..."

Journal • Retrospective data • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry

A Vortioxetine-Glycyrrhizic Acid Supramolecular Complex: Synthesis and Cellular Effects on Microglial and Blood Cells Under Inflammatory and Glucocorticoid Challenge. (PubMed, Biomedicines) - " The Vort:Na2GA supramolecular complex enhances the physicochemical and pharmacological profile of vortioxetine, reduces inflammation-associated myeloid cell populations, and preserves glucocorticoid sensitivity. These findings support its further evaluation as a potential therapeutic agent for depressive disorders with inflammatory and HPA axis-related components."

Journal • CNS Disorders • Depression • Inflammation • Mood Disorders • Psychiatry • FKBP5 • NR1D1 • NR3C1

Bioequivalence of a Generic Vortioxetine 20 mg Tablet in Healthy Mexican Volunteers Under Fasting Conditions. (PubMed, Pharmaceuticals (Basel)) - P1 | " The generic vortioxetine formulation is bioequivalent to the reference product, supporting its therapeutic interchangeability for the treatment of MDD. NCT07624357."

Journal • CNS Disorders • Cognitive Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Vortioxetine Related Hypertriglyceridemia in a Young Male. (PubMed, J Clin Psychopharmacol) - No abstract available

Journal • Dyslipidemia • Hypertriglyceridemia

Hepatic Inflammation and Apoptosis in Socially Isolated Rats: Effects of Vortioxetine Treatment. (PubMed, Iran J Pharm Res) - "Vortioxetine treatment was associated with partial attenuation of these alterations. These findings are limited to the measured endpoints and do not establish direct functional effects."

Journal • Preclinical • CNS Disorders • Depression • Inflammation • Oncology • Psychiatry • CASP3 • IL6 • KRT18 • NFKB1 • TNFA

Emerging pharmacological and neuromodulation interventions for suicidal ideation and behaviour. (PubMed, Eur Neuropsychopharmacol) - "Encouraging results were reported for NMDA-related drugs (NRX-101 and high-dose d-cycloserine; amantadine in Borna disease virus-1-positive depression), opioid-system modulation (buprenorphine at ultra-low and high doses in distinct populations), ayahuasca in major and treatment-resistant depression, and adjunctive pimavanserin. Smaller effects were observed for vortioxetine augmentation and insomnia-targeted zolpidem. Large observational datasets reported associations between lower suicidality and folic acid, benztropine, testosterone initiation in transgender adults, and non-vitamin K oral anticoagulants versus warfarin, whereas non-medical cannabis use was associated with worse SI trajectories. Neuromodulation evidence implicated accelerated or targeted repetitive transcranial magnetic stimulation, theta-burst stimulation, and magnetic seizure therapy for SI reduction, with longer-term observational support for vagus nerve stimulation. Future trials should prespecify..."

Journal • Review • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Epilepsy • Insomnia • Psychiatry • Sleep Disorder • Suicidal Ideation

Systemic Drug Effects in Vortioxetine-Induced Time-Series Datasets. (PubMed, Int J Mol Sci) - "Additionally, an analysis of the independent datasets generated at 6 and 22 h after the vortioxetine injection identified the most distinct variable genes between the two time points: CRK (1.96) and JUN (-3.02) for the ERBB signaling pathway, and BRAF (1.30) and MAP2K2 (-1.92) for the GLIOMA pathway. We conclude that vortioxetine, an antidepressant, decreases JUN, a proto-oncogene involved in the ERBB signaling pathway, and CCND1, another proto-oncogene involved in the GLIOMA pathway, over time in glioblastoma cells."

Journal • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • BRAF • CCND1 • CDK4 • MAP2K2 • PAK6

A comparative analysis of vortioxetine vs. escitalopram on the clinical profile of patients with major depressive disorder. (PubMed, J Family Med Prim Care) - "Both escitalopram and vortioxetine effectively reduce depressive symptoms in patients with MDD, with escitalopram showing a more rapid onset of symptom relief. Further long-term studies are warranted to assess the sustained efficacy and cognitive benefits of both medications in diverse patient populations."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

From Visceral Pain to Emotional Distress: Comparative Effectiveness of Antispasmodics and Antidepressants in Irritable Bowel Syndrome - Systematic Review and Network Meta-analysis. (PubMed, J Gastrointestin Liver Dis) - "Imipramine and alverine/simethicone were superior for reducing abdominal pain, whereas flupentixol-melitracen, peppermint oil, fluoxetine, and vortioxetine demonstrated the strongest anxiolytic effects. Effective options for depression included imipramine, venlafaxine, flupentixol-melitracen, desipramine, and vortioxetine. Notably, amitriptyline uniquely improved overall IBS severity scores, while otilonium bromide, venlafaxine, amitriptyline, and cumin sofouf provided the greatest benefits for QoL. These findings clarify comparative efficacy and may guide tailored pharmacotherapy strategies for IBS patients."

HEOR • Journal • Retrospective data • Review • CNS Disorders • Depression • Gastrointestinal Disorder • Mood Disorders • Pain • Psychiatry

Disposable screen-printed electrodes modified with oxygen-terminated moalb-derived mbene for low-potential detection of vortioxetine. (PubMed, Mikrochim Acta) - "Under optimized DPV conditions, the sensor exhibits two linear ranges (0.001-0.090 µM and 0.13-3.80 µM) due to surface-site saturation and diffusion contributions, with high sensitivity evidenced by a 1.0 nM detection limit, repeatability of 0.80% RSD (n = 8), and fabrication reproducibility of 2.9% RSD (n = 5). The platform also demonstrates selectivity against structurally related antidepressants and representative urine interferents, with recoveries of 96.7-109.1% in PBS-diluted urine using a portable potentiostat."

Journal

The METOD study: exploring metabolism, emotional blunting and treatment outcomes in depression - A naturalistic, two-phase observational protocol. (PubMed, Front Pharmacol) - "The study consists of two phases with distinct hypotheses: phase I) evaluating emotional blunting along other clinical/psychopathological variables as potential predictors of treatment non-response to SSRI/SNRI in MDD, and phase II) assessing relationships between IR and treatment non-response to vortioxetine in MDD...Validated clinical assessment tools are administered alongside anthropometric and laboratory evaluations. By examining these interrelations within a naturalistic cohort treated in accordance with current clinical standards, this innovative study-with its strong emphasis on patient-reported outcomes-may increase insight into the lived experience of depression, enhance understanding of the pathophysiological mechanisms shaping its diverse symptomatology, and provide a foundation for more precisely targeted therapeutic approaches."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry